EYEN - Eyenovia, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.7552
+0.0052 (+0.11%)
As of 11:34AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.7500
Open4.7100
Bid4.6600 x 900
Ask4.8400 x 1300
Day's Range4.7100 - 4.9500
52 Week Range2.4000 - 8.3080
Volume22,101
Avg. Volume53,242
Market Cap57.153M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.8700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it has initiated its MicroPine Phase III program with the first patient enrolled in its CHAPERONE study. The CHAPERONE study is a U.S.-based, multi-center, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age. The study will investigate the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovia’s proprietary atropine topical micro-formulation delivered by the Optejet™ dispenser.

  • GlobeNewswirelast month

    Eyenovia Reports First Quarter 2019 Financial Results

    NEW YORK, May 14, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • Introducing Eyenovia (NASDAQ:EYEN), The Stock That Dropped 33% In The Last Year
    Simply Wall St.last month

    Introducing Eyenovia (NASDAQ:EYEN), The Stock That Dropped 33% In The Last Year

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Eyenovia, Inc. (NASDAQ:EYEN) share price has gained som...

  • GlobeNewswire2 months ago

    Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results

    NEW YORK, May 01, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire3 months ago

    Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results

    NEW YORK, March 27, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire3 months ago

    Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

    NEW YORK, March 13, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire4 months ago

    Eyenovia to Participate in Two Upcoming Investor Conferences

    NEW YORK, March 04, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire4 months ago

    Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from its second MicroStat Phase III study, called MIST-2. The study examined the safety and efficacy of the Company’s first-in-class, MicroStat fixed-combination formulation, with target markets including the estimated 80 million annual pharmacologic mydriasis market in the United States. The MIST-2 study was a U.S.-based, multi-center, randomized, double-masked, superiority trial that enrolled 70 subjects, in whom both eyes were treated on separate days with Eyenovia's proprietary MicroStat fixed combination formulation of phenylephrine 2.5% and tropicamide 1%.

  • GlobeNewswire4 months ago

    Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering

    NEW YORK, Feb. 13, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire4 months ago

    Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate the CHAPERONE study - the Company's Phase III registration trial of MicroPine to reduce the progression of myopia in children. Currently, there are no FDA-approved therapies to slow the progression of myopia, a condition that, if uncontrolled, can in some cases be associated with major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment.

  • ACCESSWIRE4 months ago

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / In January, the trend in biotech stocks appeared to be on a positive sloping trajectory as the IBB capped off its strongest month in almost a year. Below ...

  • ACCESSWIRE5 months ago

    Biotechs Investors Are Flocking To

    HENDERSON, NV / ACCESSWIRE / January 31, 2019 / Below are a few biotechnology stocks seeing a growing amount of investor interest which is the precursor for long term bull runs. One company who's on the ...

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)

    With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • GlobeNewswire5 months ago

    Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from the MicroStat Phase 3 MIST-1 study. The study examined the safety and efficacy of the Company’s first-in-class, MicroStat fixed-combination formulation, with target markets including the estimated 80 million annual pharmacologic mydriasis market in the United States.

  • Do Institutions Own Eyenovia, Inc. (NASDAQ:EYEN) Shares?
    Simply Wall St.6 months ago

    Do Institutions Own Eyenovia, Inc. (NASDAQ:EYEN) Shares?

    A look at the shareholders of Eyenovia, Inc. (NASDAQ:EYEN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...

  • ACCESSWIRE6 months ago

    4 Healthcare Stocks to Watch on Wednesday (12/19/18)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Eyenovia Inc (EYEN), Teladoc Inc (TDOC), and Allscripts Healthcare Solutions, Inc. (MDRX), are four healthcare stocks worth paying attention to the healthcare industry presses onward. Premier Health Group, Inc (OTC:PHGRF) (CSE:PHGI) a company that is dominating the telehealth sector of the healthcare industry, has seen a strong month of bullish trading, with shares of the company climbing as much as 31% in a 30-day period. The Company has enjoyed impressive growth following their announcement earlier this week regarding the company's signing into a binding LOI to acquire all of the outstanding securities of Cloud Practice Inc.

  • GlobeNewswire6 months ago

    Eyenovia Prices Public Offering of Common Stock

    Eyenovia, Inc. (“Eyenovia” or the “Company”) (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, has priced its underwritten public offering of 1,200,000 shares of common stock at an offering price of $2.45 per share. All of the shares are being offered by the Company. The Company expects to receive gross proceeds from the offering, excluding the exercise of the over-allotment option, if any, of approximately $2.9 million, excluding underwriting discounts and commissions and other offering-related expenses.

  • GlobeNewswire7 months ago

    Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study

    Eyenovia, Inc. (EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study and enrolled the first patient in its second Phase III study, the MIST-2 trial, for the Company’s Phase III MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam. Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer commented, “We are pleased to have swiftly completed enrollment in the Phase III MIST-1 study, our first pivotal trial of MicroStat for pharmacologic mydriasis, in line with our recruitment expectations.

  • GlobeNewswire7 months ago

    Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability

    Eyenovia, Inc. (EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-review journal Clinical Ophthalmology. The topline results of the study were first reported by the Company earlier this year. This is the first study to demonstrate the effect of Eyenovia micro-dose on intraocular pressure (IOP) lowering, which is the main treatment paradigm for conditions such as glaucoma.

  • Eyenovia Initiates Phase III Study for Mydriasis Candidate
    Zacks7 months ago

    Eyenovia Initiates Phase III Study for Mydriasis Candidate

    Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.

  • Benzinga7 months ago

    The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...

  • Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
    PR Newswire7 months ago

    Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study

    NEW YORK, Nov. 26, 2018 /PRNewswire/ -- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first of two Phase III trials (MIST-1 and MIST-2) of the Company's MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam. The studies will investigate the safety and efficacy of the Company's first-in-class fixed-combination phenylephrine 2.5% - tropicamide 1% ophthalmic solution, administered as a micro-dose using the Optejet™ dispenser. Pharmacologic mydriasis is an important part of an estimated 80 million office-based comprehensive and diabetic eye exams performed each year in the United States and is essential for the standard dilated retinal fundoscopic examination.